PURPOSE: To review the cases of viral retinitis after intravitreal steroid administration at a single center, to estimate the incidence, and to propose risk factors for its occurrence. DESIGN: Retrospective, observational case series. METHODS: Seven hundred thirty-six intravitreal triamcinolone (IVTA) injections were administered in the clinic and operating room by 3 retina specialists at a single academic medical center between September 2002 and November 2008. Inclusion criteria were simply a history of 1 or more IVTA injections during the period. The overall incidence of viral retinitis after IVTA injection was calculated. Subsequently, a chart audit was performed to estimate the number of patients with immune-altering conditions who had received IVTA during the period, and the incidence within this subgroup was calculated. RESULTS: Viral retinitis developed after IVTA injection in 3 patients, yielding an overall incidence of 3 in 736 or 0.41%. An estimated 334 injections were administered to patients with an immune-altering condition, including diabetes. All 3 of the patients in whom viral retinitis developed after IVTA injection possessed abnormal immune systems, yielding an incidence rate of 3 in 334 or 0.90% within this subgroup. CONCLUSIONS: Our high reported incidence for this potentially devastating complication can be attributed to multiple factors, including coexisting medical immunocompromising comorbidities, a higher dose with a longer duration of local immunosuppression in the vitreous, multiple injections, as well as previous viral retinitis. Caution with a high index of clinical suspicion and frequent follow-up is advised in patients receiving IVTA injection with potentially immune-altering conditions, even after apparent immune recovery. (c) 2010 Elsevier Inc. All rights reserved.
PURPOSE: To review the cases of viral retinitis after intravitreal steroid administration at a single center, to estimate the incidence, and to propose risk factors for its occurrence. DESIGN: Retrospective, observational case series. METHODS: Seven hundred thirty-six intravitreal triamcinolone (IVTA) injections were administered in the clinic and operating room by 3 retina specialists at a single academic medical center between September 2002 and November 2008. Inclusion criteria were simply a history of 1 or more IVTA injections during the period. The overall incidence of viral retinitis after IVTA injection was calculated. Subsequently, a chart audit was performed to estimate the number of patients with immune-altering conditions who had received IVTA during the period, and the incidence within this subgroup was calculated. RESULTS:Viral retinitis developed after IVTA injection in 3 patients, yielding an overall incidence of 3 in 736 or 0.41%. An estimated 334 injections were administered to patients with an immune-altering condition, including diabetes. All 3 of the patients in whom viral retinitis developed after IVTA injection possessed abnormal immune systems, yielding an incidence rate of 3 in 334 or 0.90% within this subgroup. CONCLUSIONS: Our high reported incidence for this potentially devastating complication can be attributed to multiple factors, including coexisting medical immunocompromising comorbidities, a higher dose with a longer duration of local immunosuppression in the vitreous, multiple injections, as well as previous viral retinitis. Caution with a high index of clinical suspicion and frequent follow-up is advised in patients receiving IVTA injection with potentially immune-altering conditions, even after apparent immune recovery. (c) 2010 Elsevier Inc. All rights reserved.
Authors: Douglas A Jabs; Mark L Van Natta; John H Kempen; Peter Reed Pavan; Jennifer I Lim; Robert L Murphy; Larry D Hubbard Journal: Am J Ophthalmol Date: 2002-01 Impact factor: 5.258
Authors: Paul M Beer; Sophie J Bakri; Ravinder J Singh; Weiguo Liu; George B Peters; Michael Miller Journal: Ophthalmology Date: 2003-04 Impact factor: 12.079
Authors: David R Fintak; Gaurav K Shah; Kevin J Blinder; Carl D Regillo; John Pollack; Jeffrey S Heier; Hussein Hollands; Sanjay Sharma Journal: Retina Date: 2008 Nov-Dec Impact factor: 4.256
Authors: Ako Takakura; Howard H Tessler; Debra A Goldstein; Yan Guex-Crosier; Chi-Chao Chan; Diane M Brown; Jennifer E Thorne; Robert Wang; Emmett T Cunningham Journal: Ocul Immunol Inflamm Date: 2014-03-21 Impact factor: 3.070